Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

[Aspirin resistance].

Milicić D, Skorić B.

Lijec Vjesn. 2011 Sep-Oct;133(9-10):337-42. Review. Croatian.

PMID:
22165084
2.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

3.

Aspirin resistance or variable response or both?

Cheng X, Chen WH, Simon DI.

Am J Cardiol. 2006 Nov 20;98(10A):11N-17N. Epub 2006 Sep 28. Review.

PMID:
17097412
4.

Aspirin: promise and resistance in the new millennium.

Patrono C, Rocca B.

Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s25-32. doi: 10.1161/ATVBAHA.107.160481. Epub 2008 Jan 3. Review.

5.

Aspirin and clopidogrel resistance: an emerging clinical entity.

Wang TH, Bhatt DL, Topol EJ.

Eur Heart J. 2006 Mar;27(6):647-54. Epub 2005 Dec 19. Review.

6.
7.

The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.

Hennekens CH, Schneider WR.

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. Review.

PMID:
18095910
8.

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.

Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R.

Eur Heart J. 2009 Feb;30(4):426-35. doi: 10.1093/eurheartj/ehn562. Epub 2009 Jan 27. Review.

9.

Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.

Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA.

Catheter Cardiovasc Interv. 2009 Jan 1;73(1):1-14. doi: 10.1002/ccd.21782. Review.

PMID:
19089929
10.

Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?

Mohler ER 3rd.

Catheter Cardiovasc Interv. 2009 Jul 1;74 Suppl 1:S1-6. doi: 10.1002/ccd.21995. Review.

PMID:
19213065
11.

Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.

Poredos P, Jezovnik MK.

Int Angiol. 2010 Feb;29(1):20-6. Review.

PMID:
20224527
12.

Aspirin resistance.

Howard PA.

Ann Pharmacother. 2002 Oct;36(10):1620-4. Review.

PMID:
12243613
13.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

14.

Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact.

Papathanasiou A, Goudevenos J, Tselepis AD.

Curr Pharm Des. 2009;15(10):1085-94. Review.

PMID:
19355950
15.

Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.

Spinler SA.

Pharmacotherapy. 2009 Jul;29(7):812-21. doi: 10.1592/phco.29.7.812. Review.

PMID:
19558255
16.

Aspirin resistance.

Mosorjakova D, Paluch Z, Alusík S.

Bratisl Lek Listy. 2007;108(1):7-13. Review.

PMID:
17685000
18.

The role of aspirin in cardiovascular prevention: implications of aspirin resistance.

Gasparyan AY, Watson T, Lip GY.

J Am Coll Cardiol. 2008 May 13;51(19):1829-43. doi: 10.1016/j.jacc.2007.11.080. Review.

19.
20.

Antiplatelet therapy in the prevention of ischaemic stroke.

Verry M, Panak E, Cazenave JP.

Nouv Rev Fr Hematol. 1994 Jun;36(3):213-28. Review.

PMID:
7971242
Items per page

Supplemental Content

Write to the Help Desk